Corient Private Wealth LLC Purchases 5,069 Shares of DaVita Inc. $DVA

Corient Private Wealth LLC lifted its position in DaVita Inc. (NYSE:DVA) by 22.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 27,559 shares of the company’s stock after buying an additional 5,069 shares during the quarter. Corient Private Wealth LLC’s holdings in DaVita were worth $3,131,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership boosted its stake in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares in the last quarter. Norges Bank acquired a new position in shares of DaVita during the fourth quarter worth $49,164,000. Man Group plc lifted its holdings in shares of DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of DaVita by 138.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after purchasing an additional 269,015 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its position in shares of DaVita by 2,905.7% in the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after purchasing an additional 220,628 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

Shares of DVA opened at $216.83 on Friday. The company’s fifty day moving average price is $188.58 and its 200-day moving average price is $152.49. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $217.04. The firm has a market capitalization of $13.92 billion, a PE ratio of 20.11, a price-to-earnings-growth ratio of 0.71 and a beta of 0.91.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the business posted $2.00 EPS. The firm’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts anticipate that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The SEC filing for this sale provides additional information. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

DVA has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Truist Financial raised their price target on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. TD Cowen upped their price objective on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Finally, UBS Group increased their price objective on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $199.17.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.